Gilead Sciences, Inc. stock price

Today's NASDAQ:GILD chart, history & news

Price:
66.98 USD
Change:
-1.01 (-1.49%)

Key stats

Price open 67.74
Previous close 67.99
Market cap 83.96B
Volume 5.97M
Day high
Day low
Year high 81.47
Year low 56.65
Year to date change 13.48%
P/E ratio 66.98
Company Profile
Fundamentals
Insider Information
News

About Gilead Sciences, Inc.

Gilead Sciences Inc. casts itself as a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for addressing various unmet medical needs. The company came into being as a brainchild of Michael L Riordan in 1987.

Headquartered in Foster California, the company specializes in the development of treatments for HIV Hepatitis B Hepatitis C and Influenza. Its lead products include Descovy and Truvada for the treatment of HIV infection and Harvoni for the treatment of liver diseases.

The company has grown through mergers and acquisitions. Its biggest acquisition to date is the purchase of Pharmasset inc. in a deal that cost it $10.4 billion. Its other notable acquisition is YM Biosciences for $510 million.

 Gilead Sciences Inc. went public in 1992 and got listed on the NASDAQ Stock Exchange in an Initial Public Offering that raised $86.25 million.

Company information

Company name
Gilead Sciences, Inc.
Exchange
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Daniel O'Day
Address
333 Lakeside Dr, Foster city, California, 94404-1147
Country
United States
Contact information
16505743000
Website
https://www.gilead.com/

Related companies